홍민희
#폐암#두경부암#식도암#원발미상암#항암약물치료#신약치료
|
학력
2005 연세대학교 의과대학 졸업
2015 연세대학교 의과대학 석사
2015 연세대학교 의과대학 석사
경력
2005-2006 세브란스병원 인턴 수료
2006-2010 세브란스병원 전공의 수료
2010-2013 공중보건의 (강화병원 내과 과장)
2013-2014 세브란스병원 종양내과 강사
2014-2015 서울대학교 보라매병원 강사
2015-2016 MSD/Merck oncology 의학부 이사 (medical advisor)
2016-현 재 연세의료원 연세암병원 종양내과 임상조교수
2006-2010 세브란스병원 전공의 수료
2010-2013 공중보건의 (강화병원 내과 과장)
2013-2014 세브란스병원 종양내과 강사
2014-2015 서울대학교 보라매병원 강사
2015-2016 MSD/Merck oncology 의학부 이사 (medical advisor)
2016-현 재 연세의료원 연세암병원 종양내과 임상조교수
논문
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat. 2009 Jun;41(2):67-72
Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. Cancer Res Treat. 2009 Dec;41(4):196-204.
Prognosis of pN3 stage gastric cancer. Cancer Res Treat. 2009 Jun;41(2):73-9.
Clinical value of ezrin expression in primary osteosarcoma. Cancer Res Treat. 2009 Sep;41(3):138-44.
Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. Cancer Chemother Pharmacol. 2010 Sep;66(4):797-805.
Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology. 2011;80(5-6):395-405.
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. Cancer Chemother Pharmacol. 2014 Oct;74(4):799-808.
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci Rep. 2016 Nov 14;6:36956.
Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma. Ann Oncol. 2017 Jun 1;28(6):1250-1259.
Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis. Oncotarget. 2017 May 10. doi: 10.18632/oncotarget.
Povidone-iodine for the management of oral mucositis during cancer therapy. Oncol Rev. 2017 Sep 15;11(2):341.
Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Head Neck. 2018 Jan;40(1):55-62.
Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy.
LUNG CANCER 136/ :30-36,2019
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
ANNALS OF ONCOLOGY 30/7 :1,104-1,113,2019
Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors
CANCER CHEMOTHERAPY AND PHARMACOLOGY 84/2 :405-414,2019
A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs.
LUNG CANCER 134/ :46-51,2019
Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 145/6 :1,613-1,623,2019
YH25448, an irreversible EGFR-TKI with Potent Intracranial Activity in EGFR mutant non-smallcell lung cancer
CLINICAL CANCER RESEARCH 25/8 :2,575-2,587,2019
Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma.
LUNG CANCER 131/ :139-146,2019
Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
YONSEI MEDICAL JOURNAL 60/6 :525-534,2019
Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate
PLOS ONE 14/3 :e0214291-,2019
ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
ONCOGENE 37/3 :377-388,2018
Characteristics and Outcome of ROS1-Positive Non?Small Cell Lung Cancer Patients in Routine Clinical Practice
JOURNAL OF THORACIC ONCOLOGY 13/9 :1,373-1,382,2018
Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.
CANCER RESEARCH 78/12 :3,350-3,362,2018
Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
LUNG CANCER 124/ :168-178,2018
Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival
LUNG CANCER 121/ :12-17,2018
Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK 40/1 :55-62,2018
Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization.
ONCOTARGET 8/50 :87,234-87,243,2017
Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis.
ONCOTARGET 8/39 :65,111-65,122,2017
Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.
ANNALS OF ONCOLOGY 28/6 :1,250-1,259,2017
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
SCIENTIFIC REPORTS 6/36956 :1-12,2016
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane
CANCER CHEMOTHERAPY AND PHARMACOLOGY 74/4 :799-808,2014
Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles
ONCOLOGY 80/5-6 :395-405,2011
Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design
CANCER CHEMOTHERAPY AND PHARMACOLOGY 66/4 :797-805,2010
Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials
Cancer Research And Treatment 41/4 :196-204,2009
clinical value of ezrin expression in primary osteosarcoma
Cancer Research And Treatment 41/3 :138-144,2009
Prognosis of pN3 stage gastric cancer
Cancer Research And Treatment 41/2 :73-79,2009
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in korea
Cancer Research And Treatment 41/2 :67-72,2009
Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. Cancer Res Treat. 2009 Dec;41(4):196-204.
Prognosis of pN3 stage gastric cancer. Cancer Res Treat. 2009 Jun;41(2):73-9.
Clinical value of ezrin expression in primary osteosarcoma. Cancer Res Treat. 2009 Sep;41(3):138-44.
Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. Cancer Chemother Pharmacol. 2010 Sep;66(4):797-805.
Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology. 2011;80(5-6):395-405.
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. Cancer Chemother Pharmacol. 2014 Oct;74(4):799-808.
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci Rep. 2016 Nov 14;6:36956.
Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma. Ann Oncol. 2017 Jun 1;28(6):1250-1259.
Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis. Oncotarget. 2017 May 10. doi: 10.18632/oncotarget.
Povidone-iodine for the management of oral mucositis during cancer therapy. Oncol Rev. 2017 Sep 15;11(2):341.
Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Head Neck. 2018 Jan;40(1):55-62.
Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy.
LUNG CANCER 136/ :30-36,2019
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
ANNALS OF ONCOLOGY 30/7 :1,104-1,113,2019
Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors
CANCER CHEMOTHERAPY AND PHARMACOLOGY 84/2 :405-414,2019
A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs.
LUNG CANCER 134/ :46-51,2019
Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 145/6 :1,613-1,623,2019
YH25448, an irreversible EGFR-TKI with Potent Intracranial Activity in EGFR mutant non-smallcell lung cancer
CLINICAL CANCER RESEARCH 25/8 :2,575-2,587,2019
Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma.
LUNG CANCER 131/ :139-146,2019
Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
YONSEI MEDICAL JOURNAL 60/6 :525-534,2019
Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate
PLOS ONE 14/3 :e0214291-,2019
ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
ONCOGENE 37/3 :377-388,2018
Characteristics and Outcome of ROS1-Positive Non?Small Cell Lung Cancer Patients in Routine Clinical Practice
JOURNAL OF THORACIC ONCOLOGY 13/9 :1,373-1,382,2018
Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.
CANCER RESEARCH 78/12 :3,350-3,362,2018
Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
LUNG CANCER 124/ :168-178,2018
Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival
LUNG CANCER 121/ :12-17,2018
Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK 40/1 :55-62,2018
Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization.
ONCOTARGET 8/50 :87,234-87,243,2017
Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis.
ONCOTARGET 8/39 :65,111-65,122,2017
Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.
ANNALS OF ONCOLOGY 28/6 :1,250-1,259,2017
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
SCIENTIFIC REPORTS 6/36956 :1-12,2016
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane
CANCER CHEMOTHERAPY AND PHARMACOLOGY 74/4 :799-808,2014
Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles
ONCOLOGY 80/5-6 :395-405,2011
Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design
CANCER CHEMOTHERAPY AND PHARMACOLOGY 66/4 :797-805,2010
Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials
Cancer Research And Treatment 41/4 :196-204,2009
clinical value of ezrin expression in primary osteosarcoma
Cancer Research And Treatment 41/3 :138-144,2009
Prognosis of pN3 stage gastric cancer
Cancer Research And Treatment 41/2 :73-79,2009
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in korea
Cancer Research And Treatment 41/2 :67-72,2009
저서
저서 내용이 없습니다.
보도자료
[조선비즈]조병철 연세암병원 교수팀, 난치성 폐암치료제로 국제 폐암진료지침...
http://biz.chosun.com/site/data/html_dir/2017/12/27/2017122701237.html
[연합뉴스]“연세암병원-노바티스, 폐암 치료제 공동 개발한다” - 종양내과...
http://www.yonhapnews.co.kr/bulletin/2017/08/31/0200000000AKR20170831172400017.HTML?input=1195m
[서울경제]“노바티스, 바이엘, “생큐 코리아 연구팀” - 종양내과 조병철...
http://www.sedaily.com/NewsView/1OFYIJCJ00
http://biz.chosun.com/site/data/html_dir/2017/12/27/2017122701237.html
[연합뉴스]“연세암병원-노바티스, 폐암 치료제 공동 개발한다” - 종양내과...
http://www.yonhapnews.co.kr/bulletin/2017/08/31/0200000000AKR20170831172400017.HTML?input=1195m
[서울경제]“노바티스, 바이엘, “생큐 코리아 연구팀” - 종양내과 조병철...
http://www.sedaily.com/NewsView/1OFYIJCJ00
포스팅
포스팅 내용이 없습니다.
영상자료
영상자료 내용이 없습니다.
발표자료
발표자료 내용이 없습니다.